Table 2.
Baseline characteristics (pooled data) (n=1788) | n (%)* |
---|---|
Age (<75 years) | 1146 (64.1) |
Gender (male) | 1196 (66.9) |
Discharge diagnoses (NSTEMI) | 1119 (62.6) |
Length of hospital stay (days) (mean±SD) | 5±4.97 |
Systolic blood pressure (mm Hg) | |
High (≥160) | 552 (30.9) |
Normal to slightly elevated (81–159) | 1236 (69.1) |
Low (≤80) | 0 (0) |
Heart rate (bpm) | |
Tachycardia (≥110) | 103 (5.8) |
Normal (51–109) | 1634 (91.4) |
Bradycardia (≤50) | 51 (2.8) |
Resuscitation at admission | 33 (1.9) |
Cardiogenic shock | 7 (0.4) |
In-hospital heart failure | 103 (5.8) |
ST deviations on ECG | 810 (45.3) |
History of coronary artery disease | 252 (14.1) |
History of peripheral vascular disease | 131 (7.3) |
Previous (U)A | 432 (24.1) |
Previous MI | 499 (27.9) |
Previous PCI | 523 (29.3) |
Previous CABG | 289 (16.2) |
MI or PCI/CABG 6 months prior to admission | 125 (7) |
Diabetes mellitus | 451 (25.2) |
Hypertension | 936 (52.4) |
Renal failure | 88 (4.9) |
Chronic heart failure | 101 (5.7) |
Hypercholesterolaemia† | 986 (55.1) |
Obesity (BMI>30) | 203 (11.3) |
Smoking | 427 (23.9) |
Former smoker | 350 (19.6) |
Coronary stenosis (≥50%) | 192 (10.8) |
Positive family history | 618 (34.6) |
Coronary catheterisation | 1346 (75.3) |
Management strategy | |
Pharmacological therapy | 754 (42.2) |
(scheduled) PCI | 846 (47.3) |
(scheduled) CABG | 188 (10.5) |
*Data are presented in n (%), unless stated otherwise.
†Defined as statin use prior to admission, or described in patients history (elevated cholesterol levels, hyperlipidaemia or hypercholesterolaemia).
BMI, body mass index; CABG, coronary artery bypass grafting; MI, myocardial infarction; PCI, percutaneous coronary intervention; (U)A, (unstable)angina.